$Verastem (VSTM.US)$
Verastem Oncology Outlines 2025 Strategic Priorities and Milestones for Novel Pipeline Targeting RAS/MAPK Pathway-Driven Cancers
Thursday, 23rd January at 7:30 am
Avutometinib plus defactinib granted priority review by FDA, under the accelerated approval pathway, for recurrent KRAS mutant LGSOC; PDUFA action date set for June 30, 2025
Potential U.S. commercial launch in recurrent KRAS mutant LGSOC planned for mid-2025
RAMP 205 trial in 1L metastatic pancreatic cancer cont...

$Verastem (VSTM.US)$ 👀

$Verastem (VSTM.US)$
Verastem Oncology Exercises Option Early to License VS-7375, an Oral KRAS G12D (ON/OFF) Inhibitor, from GenFleet Therapeutics and Provides Preliminary Clinical Update on Phase 1 Study in China
Tuesday, 14th January at 7:30 am
VS-7375 is a potential best-in-class oral and selective KRAS G12D (ON/OFF) inhibitor currently in Phase 1 development in China in advanced KRAS G12D mutant solid tumors; Verastem anticipates filing a U.S. IND application for VS-7375 during Q1 2025​ a...

$Verastem (VSTM.US)$
Verastem Oncology Announces Debt Refinancing with Oberland Capital and Strategic Commercialization Partnership with IQVIA to Support Potential Launch in Recurrent KRAS Mutant Low-Grade Serous Ovarian Cancer in Mid-2025
Monday, 13th January at 7:30 am
Company cash, cash equivalents, and investments of $88.8 million as of December 31, 2024; pro forma cash position of $128.6 million including debt refinancing and equity issuance provides cash runway beyond FDA approval
Veras...

$Verastem (VSTM.US)$ where is this 6.28 resistance you speak of?

$Verastem (VSTM.US)$
VSTM Up as NDA for Ovarian Cancer Combo Gets FDA's Priority Review
Big News came out

$Verastem (VSTM.US)$Up UpUp

$Verastem (VSTM.US)$ Nice to see ya still got some life in ya

$Verastem (VSTM.US)$ emotion points up

$Verastem (VSTM.US)$ $8.5🚀🚀